MX386542B - Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. - Google Patents

Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.

Info

Publication number
MX386542B
MX386542B MX2015008396A MX2015008396A MX386542B MX 386542 B MX386542 B MX 386542B MX 2015008396 A MX2015008396 A MX 2015008396A MX 2015008396 A MX2015008396 A MX 2015008396A MX 386542 B MX386542 B MX 386542B
Authority
MX
Mexico
Prior art keywords
compound
isoindol
dihydro
derivatives
pharmaceutical compositions
Prior art date
Application number
MX2015008396A
Other languages
English (en)
Spanish (es)
Other versions
MX2015008396A (es
Inventor
Hyun Ju Cha
Im Sook Min
Jeong Eun Na
Joong Myung Cho
Seonggu Ro
Sool Ki Kwon
Yong Rae Hong
Original Assignee
Crystalgenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics Inc filed Critical Crystalgenomics Inc
Publication of MX2015008396A publication Critical patent/MX2015008396A/es
Publication of MX386542B publication Critical patent/MX386542B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2015008396A 2012-12-28 2013-12-26 Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. MX386542B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746980P 2012-12-28 2012-12-28
PCT/KR2013/012204 WO2014104757A1 (ko) 2012-12-28 2013-12-26 Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물

Publications (2)

Publication Number Publication Date
MX2015008396A MX2015008396A (es) 2016-04-15
MX386542B true MX386542B (es) 2025-03-18

Family

ID=51021712

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008396A MX386542B (es) 2012-12-28 2013-12-26 Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
MX2021011563A MX2021011563A (es) 2012-12-28 2013-12-26 Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011563A MX2021011563A (es) 2012-12-28 2013-12-26 Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.

Country Status (15)

Country Link
US (4) US9758508B2 (enExample)
EP (2) EP2940014B1 (enExample)
JP (2) JP6325573B2 (enExample)
KR (1) KR102009163B1 (enExample)
CN (1) CN104995184B (enExample)
AU (3) AU2013371146C1 (enExample)
BR (1) BR112015015477B1 (enExample)
CA (1) CA2896711C (enExample)
DK (1) DK2940014T3 (enExample)
ES (2) ES2696700T3 (enExample)
MX (2) MX386542B (enExample)
PL (1) PL2940014T3 (enExample)
PT (1) PT2940014T (enExample)
RU (2) RU2018138028A (enExample)
WO (1) WO2014104757A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011256380C1 (en) 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
JP6325573B2 (ja) 2012-12-28 2018-05-16 クリスタルジェノミクス・インコーポレイテッドCrystalgenomics, Inc. Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物
JP6816100B2 (ja) 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド RETキナーゼ阻害物質としての置換ピラゾロ[1,5−a]ピリジン化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
MX2019009954A (es) * 2017-02-21 2019-12-19 Aptose Biosciences Inc Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas.
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
AU2019387508A1 (en) * 2018-11-30 2021-06-10 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240091226A1 (en) * 2021-01-05 2024-03-21 Sumitomo Pharma Oncology, Inc. Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
US11926625B2 (en) * 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20033003A3 (cs) * 2001-04-12 2004-05-12 F@Áhoffmann@Laárocheáag Dihydrobenzo [b][�Ź@]diazepin@onové deriváty jako MGLUR@ antagonisty II
JP2006526648A (ja) * 2003-06-02 2006-11-24 アボット・ラボラトリーズ キナーゼ阻害剤としてのイソインドリン−1−オン化合物
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
US7745641B2 (en) * 2005-04-19 2010-06-29 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
WO2007047646A2 (en) * 2005-10-14 2007-04-26 Janssen Pharmaceutica, N.V. Substituted dihydro-isoindolones useful in treating kinase disorders
JP2009530342A (ja) * 2006-03-20 2009-08-27 エフ.ホフマン−ラ ロシュ アーゲー Btkおよびsyk蛋白キナーゼを阻害する方法
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ.ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
WO2012014017A1 (en) 2010-07-30 2012-02-02 Poly Medicure Limited Catheter introducer
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
JP6325573B2 (ja) 2012-12-28 2018-05-16 クリスタルジェノミクス・インコーポレイテッドCrystalgenomics, Inc. Btkキナーゼ抑制剤としての2,3−ジヒドロ−イソインドール−1−オン誘導体及びこれを含む薬学的組成物
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase

Also Published As

Publication number Publication date
KR102009163B1 (ko) 2019-08-09
US9758508B2 (en) 2017-09-12
RU2671847C2 (ru) 2018-11-07
AU2013371146A1 (en) 2015-07-16
DK2940014T3 (en) 2018-12-10
CA2896711A1 (en) 2014-07-03
MX2015008396A (es) 2016-04-15
EP2940014A1 (en) 2015-11-04
AU2013371146C1 (en) 2019-01-17
MX2021011563A (es) 2022-10-10
AU2020201431B2 (en) 2021-07-22
ES2696700T3 (es) 2019-01-17
JP6325573B2 (ja) 2018-05-16
US20220380346A1 (en) 2022-12-01
CN104995184A (zh) 2015-10-21
ES2929906T3 (es) 2022-12-02
CN104995184B (zh) 2018-01-02
RU2015124381A (ru) 2017-02-01
US20150336934A1 (en) 2015-11-26
EP2940014A4 (en) 2016-06-22
CA2896711C (en) 2019-12-31
EP3428161A1 (en) 2019-01-16
RU2018138028A (ru) 2019-03-21
US20210009565A1 (en) 2021-01-14
AU2018214134B2 (en) 2020-03-12
US20170362205A1 (en) 2017-12-21
BR112015015477A2 (pt) 2017-07-11
BR112015015477B1 (pt) 2022-07-12
US11230539B2 (en) 2022-01-25
AU2018214134A1 (en) 2018-08-30
KR20160058720A (ko) 2016-05-25
AU2013371146B2 (en) 2018-05-10
PT2940014T (pt) 2018-11-28
PL2940014T3 (pl) 2019-03-29
WO2014104757A1 (ko) 2014-07-03
EP3428161B1 (en) 2022-09-07
JP2016504351A (ja) 2016-02-12
JP2018109069A (ja) 2018-07-12
JP6596537B2 (ja) 2019-10-23
US10604508B2 (en) 2020-03-31
AU2020201431A1 (en) 2020-03-19
HK1259355A1 (en) 2019-11-29
EP2940014B1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
NZ708593A (en) Novel pyrazole derivative
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
MX347988B (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA201001618A1 (ru) Ингибиторы syk протеинкиназ
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
MX375484B (es) Derivados de azabencimidazol como inhibidores de pi3k beta
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
MX380928B (es) Inhibidores de kras g12c.
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12016502353A1 (en) Pharmaceutical composition
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
NZ738247A (en) 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors